Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Osimertinib
Drug: Necitumumab
Drug: Carboplatin
Drug: Alectinib
Drug: Selumetinib
Drug: Datopotamab deruxtecan
Drug: Savolitinib
Drug: Gefitinib
Drug: Selpercatinib
Drug: Pemetrexed
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2019-05-10

Last Posted Date: 2024-07-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 248

Registration Number: NCT03944772

Locations: 🇸🇪
Research Site, Stockholm, Sweden

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Phase 2

Active, not recruiting

Conditions: Testicular Cancer
Seminoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2019-05-06

Last Posted Date: 2024-06-25

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 135

Registration Number: NCT03937843

Locations: 🇨🇭
Kantonsspital Graubünden, Chur, Switzerland
🇨🇭
Hopital de Sion, Sion, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 16 locations

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3

Recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: DFP-10917
Drug: Cytarabine
Drug: Azacitidine
Drug: Decitabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: Fludarabine
Drug: Idarubicin
Drug: Venetoclax
Drug: Cladribine

First Posted Date: 2019-04-24

Last Posted Date: 2022-10-20

Lead Sponsor: Delta-Fly Pharma, Inc.

Target Recruit Count: 450

Registration Number: NCT03926624

Locations: 🇺🇸
University of California, Irvine, California, United States
🇺🇸
Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸
The University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 36 locations

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Pyrotinib
Drug: Etoposide

First Posted Date: 2019-04-22

Last Posted Date: 2019-04-22

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 32

Registration Number: NCT03923179

Locations: 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: chiauranib
Drug: etoposide
Drug: paclitaxel

First Posted Date: 2019-04-03

Last Posted Date: 2021-03-19

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 47

Registration Number: NCT03901118

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Phase 1

Terminated

Conditions: Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma
KSHV-associated Multicentric Castleman Disease

Interventions: Biological: Rituximab and Hyaluronidase Human
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Methotrexate
Drug: Doxorubicin
Biological: Rituximab
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Drug: Etoposide

First Posted Date: 2019-03-06

Last Posted Date: 2024-01-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT03864419

Locations: 🇺🇬
UCI-Fred Hutch Cancer Centre, Kampala, Uganda

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

First Posted Date: 2019-03-04

Last Posted Date: 2024-05-16

Lead Sponsor: Sanofi

Target Recruit Count: 67

Registration Number: NCT03860844

Locations: 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽
Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷
Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil

and more 38 locations

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: CC-90011
Drug: Carboplatin
Drug: Nivolumab
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2019-02-21

Last Posted Date: 2024-08-26

Lead Sponsor: Celgene

Target Recruit Count: 90

Registration Number: NCT03850067

Locations: 🇪🇸
Local Institution - 406, Majadahonda, Madrid, Spain
🇫🇷
Local Institution - 102, Marseille Cedex 5, France
🇪🇸
Local Institution - 402, Barcelona, Spain

and more 10 locations

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: M7824
Drug: Placebo
Drug: Durvalumab
Drug: Etoposide
Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Intensity Modulated Radiation Therapy (IMRT)

First Posted Date: 2019-02-15

Last Posted Date: 2024-01-16

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 153

Registration Number: NCT03840902

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas, United States
🇺🇸
Lynn Cancer Institute Center, Boca Raton, Florida, United States
🇺🇸
American Health Network of Indiana, LLC, Indianapolis, Indiana, United States

and more 101 locations

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Transformed Lymphoma

Interventions: Drug: Rituximab
Drug: Etoposide
Drug: Vincristine
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Cisplatin
Drug: Cytarabine

First Posted Date: 2019-02-12

Last Posted Date: 2022-01-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 118

Registration Number: NCT03837873

Locations: 🇨🇳
the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
the First Affiliated Hospital of Jilin University, Changchun, Jilin, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy